Dynamics of laboratory parameters during emapalumab therapy
| Parameters, mean ± SEM | Before emapalumab therapy | After emapalumab therapy | Normal range |
|---|---|---|---|
| Ferritin, µg/L | 4,480 ± 3,100 | 825 ± 282 | 20–140 |
| Triglyceride, mM/L | 3.58 ± 1 | 1.7 ± 0.2 | 0–2.3 |
| Fibrinogen, g/L | 1.4 ± 0.2 | 2.3 ± 0.2 | 2–3.93 |
| Platelet, ×109/L | 180 ± 70 | 237 ± 40 | 204–356 |
| Neutrophil counts, ×109/L | 1.0 ± 0.6 | 2.3 ± 1.0 | 2.27–5.56 |
| Hemoglobin, g/L | 106.5 ± 12 | 111 ± 13 | 115–138 |
| Parameters, mean ± SEM | Before emapalumab therapy | After emapalumab therapy | Normal range |
|---|---|---|---|
| Ferritin, µg/L | 4,480 ± 3,100 | 825 ± 282 | 20–140 |
| Triglyceride, mM/L | 3.58 ± 1 | 1.7 ± 0.2 | 0–2.3 |
| Fibrinogen, g/L | 1.4 ± 0.2 | 2.3 ± 0.2 | 2–3.93 |
| Platelet, ×109/L | 180 ± 70 | 237 ± 40 | 204–356 |
| Neutrophil counts, ×109/L | 1.0 ± 0.6 | 2.3 ± 1.0 | 2.27–5.56 |
| Hemoglobin, g/L | 106.5 ± 12 | 111 ± 13 | 115–138 |